Send to

Choose Destination
Invest New Drugs. 1994;12(1):53-5.

Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study.

Author information

University of Arkansas for Medical Science, Little Rock.


Nineteen patients with multiple myeloma resistant to standard alkylating agent therapy or to the VAD regimen received carboplatin at a planned daily dose of 100 mg/M2 on four successive days. Two patients erroneously received a four-fold higher drug dose resulting in bone marrow aplasia and death without antitumor effect in one patient with post-mortem examination. No anti-tumor effect was observed among 15 patients evaluable for response (two lacked follow-up examination of tumor markers). Major toxicities were hematologic and included grade > or = III, leukopenia in 9, thrombocytopenia in 6 and anemia in 3 of the 17 evaluable patients. Their median survival was 9 months. These results indicate that carboplatin is inactive in refractory multiple myeloma.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center